SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Research and Markets: Global Hepatitis C Therapeutics in Major Developed Markets 2013-2019

[April 23, 2014]

Research and Markets: Global Hepatitis C Therapeutics in Major Developed Markets 2013-2019

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/q3nxmh/hepatitis_c) has announced the addition of the "Global Hepatitis C Therapeutics in Major Developed Markets 2013-2019" report to their offering.

The global market has the potential to grow to a value of $18.6 billion by 2019, more than tripling the 2012 market value of $5.8 billion

Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape. The current Hepatitis C treatment landscape consists of a combination of pegylated interferon, ribavirin and, in patients infected with genotype 1 hepatitis C, one of two direct-acting antiviral agents (DAAs). Products with these mechanisms of action have performed strongly in the commercial setting, with the market leader Incivek (a DAA) having reached blockbuster sales.

However, these products are very poorly tolerated and only moderately efficacious. The approval of the DAA Sovaldi in December 2013 changed this, with a complete viral clearance being achieved in close to 100% of patients and a much improved adverse event profile compared to previous standards of therapy. In patients with genotype 2 and 3 hepatitis C, Sovaldi does not need to be administered with pegylated interferon.

A number of products in the late-stage pipeline, which promise to be even more efficacious and safe are anticipated to enter the market over the forecast period, includingseveral interferon-free therapies for genotype 1-infected patients. As a result of this, as well as an overall increase in the treated population, the authors believe the global market has the potential to grow to a value of $18.6 billion by 2019, more than tripling the 2012 market value of $5.8 billion.


Scope

  • A brief introduction to hepatitis C, including the disease's pathogenesis, risk factors and diagnosis, and detailed analyses of disease epidemiology and treatment algorithms.
  • In-depth analysis of the major antiviral drugs used in the treatment of hepatitis C, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map that compares marketed drugs in terms of safety and efficacy.
  • A comprehensive review of the pipeline for hepatitis C therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed by phase distribution, molecule type and molecular target.
  • In-depth clinical trial enrolment, trial duration and program failure rate analyses for each molecule type and mechanism of action. Additionally, clinical trial endpoints and certain selection criteria are analyzed in great depth. This section also includes an additional heat map regarding pipeline products, and a direct cross-analysis against currently marketed products.
  • Multi-scenario forecast data of the market to 2019, which takes into account the effects of the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets: US, Canada, Japan, Germany, UK, France, Italy and Spain.
  • Discussion of the drivers and barriers for market growth.
  • Analysis of licensing and co-development deals occurring in the hepatitis C market.

Key Topics Covered:

1 Tables & Figures

2 Introduction

  • Signs and Symptoms
  • Etiology and Risk Factors
  • Pathophysiology
  • Epidemiology
  • Prognosis (News - Alert)
  • Treatment

3 Marketed Products

  • Ribavirin
  • Pegasys (Peginterferon alfa 2a) and PegIntron (Peginterferon alfa 2b) - Hoffmann La Roche and Merck & Co
  • Incivek (telaprevir) - Vertex (News - Alert) Pharmaceuticals and Janssen-Cilag
  • Victrelis (boceprevir) - Merck & Co
  • Olysio (simeprevir) - Johnson and Johnson
  • Sovaldi (sofosbuvir) - Gilead Sciences
  • Heat Map for Marketed Products

4 Developmental Pipeline

  • Overall Pipeline
  • Mechanisms of Action
  • Clinical Trials
  • Promising Pipeline Drugs
  • Heat Map and Competitor Matrix for Pipeline Products
  • Conclusion

5 Market Forecast to 2019

6 Drivers and Barriers

7 Licensing and Co-development deals

8 Appendix

For more information visit http://www.researchandmarkets.com/research/q3nxmh/hepatitis_c


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved.